Loading data for XFOR — first visit, this takes a few seconds.

Alerte

X4 Pharmaceuticals Inc. (XFOR)

NasdaqCM: XFOR · Prix en temps réel · USD

4.20

-0.01 (-0.24%)

À la clôture : Aug 19, 2026, 3:20 PM

-0.24% (1D)

Aucune donnée disponible

Cours acheteur	3.08
Capitalisation boursière	418.89M
Chiffre d’affaires (ttm)	15.85M
Résultat net (ttm)	-90.14M
Bêta	0.39
EPS (ttm)	1.43
Ratio P/E (ttm)	2.95
P/E prévisionnel	-5.6
P/B (ttm)	2.61
P/S (ttm)	26.43
Earnings Date	Nov 5, 2026

Cours vendeur	5.4
Volume	184,249
Volume moy. (20D)	750,170
Ouverture	4.25
Clôture précédente	4.21
Fourchette du jour	4.20 - 4.35
Intervalle de 52 semaines	2.69 - 4.83
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de XFOR

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[En savoir plus]

Industrie Biotechnology

Secteur Healthcare

Date d’introduction Nov 16, 2017

Employés 45

Bourse NasdaqCM

Symbole boursier XFOR

Site web https://www.x4pharma.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de X4 Pharmaceuticals s’élevait à 35.11M, soit une hausse de 1,273.21% par rapport aux 2.56M de l’année précédente. Le bénéfice s’élevait à -79.2M, soit une hausse de 111.48%.

États financiers

Surprise sur les résultats

X4 Pharmaceuticals a publié ses résultats trimestriels le Aug 6, 2026 :

Chiffre d’affaires de $8.81M est inférieur aux estimations de $0, avec 346.33% croissance en glissement annuel.

EPS de -0.13 dépasse les estimations de 0.05, avec 96.25% croissance en glissement annuel.

Prochaine publication des résultats

X4 Pharmaceuticals Inc. devrait publier ses résultats le Nov 5, 2026, pendant les heures de marché.
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure

Actualités

1 semaine il y a · Zacks

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 semaine il y a · Zacks

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 mois il y a · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

3 mois il y a · Zacks

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

3 mois il y a · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Page 1 de 2

X4 Pharmaceuticals Inc. (XFOR)